Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alvogen, Inc.

http://www.alvogen.com

Latest From Alvogen, Inc.

Private Financing Round Values Alvotech At $1.5bn

Having previously announced plans for a public listing, biosimilars company Alvotech has raised tens of millions of dollars though a private placement of new shares, providing further firepower to develop its vast portfolio of candidates.

Financing Biosimilars

Ligand Set For Partnership Opportunities After Completing On Pfenex

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.

Deals Companies

What’s Next? Five Things To Look Out For In October

In October, the period during which Mylan may complete its merger with Upjohn will begin, while the FDA will begin holding monthly stakeholder meetings ahead of the third iteration of the Generic Drug User Fee Amendments program, also known as GDUFA III.

Deals Intellectual Property

Alvogen’s Lotus Picks Up Darbepoetin Alfa Rights In Asia

Lotus Pharmaceuticals has expanded its biosimilar pipeline to five by bringing in rights in Taiwan and South East Asia markets to Chong Kun Dang Pharmaceutical’s biosimilar of Kyowa Kirin’s Nesp (darbepoetin alfa).

Deals Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Alvogen Korea Co., Ltd, Lotus Pharmaceuticals
UsernamePublicRestriction

Register